WINSUN BIO(BJ:839729)2025-02-26 11:05Financial Performance - The company's operating revenue for the reporting period was CNY 269.69 million, a decrease of 14.19% compared to CNY 314.28 million in the same period last year[4]. - The net profit attributable to shareholders was CNY 41.28 million, down 28.91% from CNY 58.06 million year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 32.34 million, a decline of 27.16% compared to CNY 44.39 million in the previous year[4]. - The company's basic earnings per share decreased to CNY 0.15, down 28.57% from CNY 0.21 in the previous year[4]. Assets and Equity - The total assets at the end of the reporting period were CNY 774.43 million, a decrease of 1.70% from CNY 787.86 million at the beginning of the period[5]. - The equity attributable to shareholders was CNY 661.76 million, down 1.02% from CNY 668.55 million at the beginning of the period[5]. Revenue Decline Factors - The decline in revenue was primarily due to weak demand for animal health products in the downstream breeding industry and intensified price competition[7]. - The company's comprehensive gross profit margin decreased, and operating expenses did not decline proportionately with revenue, contributing to the drop in net profit[7]. Future Outlook - The company continues to focus on "innovation-driven development" to explore new growth drivers through R&D, product upgrades, and market expansion[6]. - Investors are advised to be cautious as the financial data for 2024 is preliminary and unaudited, with final figures to be disclosed in the annual report[8].